Further demonstration of the overexpression of the PIK3CA gene supports the identification of this alteration as a possible biomarker in the early identification of patients with IPMN at higher risk for disease progression. The gene discussed is PIK3CA; the disease is pancreatic intraductal papillary-mucinous neoplasm.